Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health epithelial cell cytology Coverage | O…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Epithelial Cell Cytology in Breast Cancer Risk Assessment

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Oscar Health's coverage stance for cytologic evaluation of breast epithelial cells (nipple aspiration, ductal lavage, fine-needle aspiration) used to diagnose, screen for, or assess risk of breast cancer; intended for providers submitting claims and seeking authorization guidance.

    Policy Summary
    PayerOscar Health
    PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment
    Policy CodePolicy N/A
    Change TypeMinor/No material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDo not use cytologic analysis of nipple aspiration, ductal lavage, or FNA to diagnose, screen for, or assess breast cancer risk; check prior authorization requirements and document medical necessity if submitting claims for listed cytopathology procedures.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredCoverage stance
    88108,88112,88172-77Referenced codes
    Sens 17% Spec 66%Study performance
    17

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Evidence items
    1Publication history

    Coverage Determination

    Not covered for diagnosis/screening/risk assessment

    Not medically necessary.

    Cytologic analysis not meeting criteria: Cytologic analysis of epithelial cells (e.g., nipple aspiration, fine‑needle aspiration [FNA], ductal lavage) to diagnose, to screen for, or to assess risk of developing breast cancer DOES NOT MEET CRITERIA.

    Determination based on lack of sufficient published scientific literature demonstrating that these tests are required and beneficial for diagnosis or treatment.

    Cytologic analysis of epithelial cells obtained by nipple aspiration, ductal lavage, or fine-needle aspiration (FNA) to diagnose, screen for, or assess risk of developing breast cancer is considered not medically necessary by this policy due to insufficient published scientific evidence demonstrating that these tests are required and beneficial for diagnosis or treatment.

    If there is a conflict between this policy and an applicable government policy (for example, Medicare Local Coverage Determinations or National Coverage Determinations, or state Medicaid rules), the government policy will be used to make the coverage determination.

    Procedure codes shown in this Medical Policy are provided only as a general reference and may not be all-inclusive; they are included to assist with billing and coding but should not be interpreted as a complete code list for all circumstances.

    Coding and Procedure References

    Referenced CPT Procedure CodesCPT
    88108Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)
    88112Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal.
    88172Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site.
    88173Cytopathology, evaluation of fine needle aspirate; interpretation and report.
    88177Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)
    Procedure CPT Codes referencedCPT
    88108Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)
    88112Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal
    88172Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site
    88173Cytopathology, evaluation of fine needle aspirate; interpretation and report
    88177Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)

    Provider Responsibilities & Expectations

    Prior Authorization

    Authorization expectation for listed cytopathology CPT codes

    Referenced cytopathology CPT codes (88108, 88112, 88172, 88173, 88177) listed in this policy may be subject to prior authorization and should be supported by documentation demonstrating medical necessity per the member’s benefit.

    • Procedure codes: 88108, 88112, 88172, 88173, 88177
    Prior Authorization

    Prior authorization may apply to listed cytopathology CPT codes

    Check the payer’s prior authorization requirements before submitting claims for cytopathology services coded with 88108, 88112, 88172, 88173, or 88177; these codes are explicitly referenced in the policy and may require authorization where applicable.

    • Codes to verify for prior authorization: 88108, 88112, 88172, 88173, 88177

    Background and Test Methods

    Nipple aspiration, ductal lavage, and fine-needle aspiration (FNA) are techniques used to collect epithelial cells for cytologic evaluation. These methods have been applied to investigate nipple discharge or to sample cells from a suspicious breast mass, and have also been explored for biomarker profiling (for example, analyses of nipple aspirate fluid). However, available evidence indicates that core needle biopsy is generally superior to FNA for establishing a tissue diagnosis of breast cancer, and fluid/cytology-based approaches have not demonstrated sufficient clinical benefit to guide diagnosis or improve outcomes.

    Abbreviations & Test Definitions

    FNA — Fine-Needle Aspiration
    TermFNA (Fine-Needle Aspiration)
    DefinitionA diagnostic procedure that uses a thin needle to aspirate cells or fluid from a breast lesion for cytologic evaluation.
    Typical use noted in policyMay be used for symptomatic relief of a cyst or possible abscess; not preferred for tissue diagnosis of suspicious breast masses (core needle biopsy preferred).
    NAF — Nipple Aspirate Fluid
    TermNAF (Nipple Aspirate Fluid)
    DefinitionFluid obtained from the nipple used to collect epithelial cells for cytologic analysis and investigational biomarker profiling (e.g., miRNA, hormones).

    Biomarkers & Research Findings

    Biomarkers referenced in NAF studies
    miRNAMicroRNA profiles in nipple aspirate fluid have been investigated as potential early breast cancer detection biomarkers (see Moelans et al. 2019).
    DHEADehydroepiandrosterone measured in nipple aspirate fluid has been studied in relation to breast cancer risk (Chatterton et al. 2016).
    Use in policymiRNA and DHEA are referenced as investigational biomarker profiling in nipple aspirate fluid— not established for clinical diagnostic or screening use.
    Reported miRNA and hormone findings in NAF studies
    Reported miRNA findingsApplication of nipple aspirate fluid miRNA profiles for early breast cancer detection has been described in the literature (Moelans et al. 2019); these remain investigational.
    Hormone concentrations

    Policy History

    2009-06evidence_publication

    Kooistra et al. published a 618-patient study reporting diagnostic value of nipple discharge cytology (European J Surg Oncol, Jun 2009).

    2016-04evidence_publication

    Chatterton et al. reported on nipple aspirate fluid hormone concentrations and breast cancer risk (Horm Cancer, Apr 2016).

    2025-02-04evidence_publication

    Zhu et al. described a new cytological evaluation method using direct nipple discharge (Scientific Reports, Feb 4, 2025).

    Policy Summary
    PayerOscar Health
    PolicyEpithelial Cell Cytology in Breast Cancer Risk Assessment
    Policy CodePolicy N/A
    Change TypeMinor/No material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDo not use cytologic analysis of nipple aspiration, ductal lavage, or FNA to diagnose, screen for, or assess breast cancer risk; check prior authorization requirements and document medical necessity if submitting claims for listed cytopathology procedures.
    SourceLink
    On This Page
    Coverage DeterminationCoding and Procedure ReferencesProvider Responsibilities & ExpectationsBackground and Test MethodsAbbreviations & Test DefinitionsBiomarkers & Research FindingsPolicy History
    Step Therapy

    Core needle biopsy preferred over FNA for suspicious breast masses

    When a tissue diagnosis is required for a suspicious breast mass, core needle biopsy is preferred over fine‑needle aspiration (FNA) because core biopsy has superior sensitivity, specificity, and provides correct histologic grading.

    • FNA is a rapid technique but less accurate than core needle biopsy and cannot reliably distinguish in situ from invasive cancer; core biopsy is superior
    Documentation Required

    Documentation and coding responsibilities

    Providers are responsible for submission of accurate documentation of services performed and must code claims according to industry-standard coding guidelines; failure to follow coding/billing guidelines may result in denial or recoupment.

    • Follow industry standards (CPT, ICD-10-CM, UB, CMS NCCI, etc.) when coding and billing
    • Accurate documentation of services performed is required for claim adjudication
    Documentation Required

    Document procedures and cytopathology interpretations consistent with listed CPT codes

    Document cytopathology procedures and interpretations in the medical record consistent with the CPT codes referenced in this policy (88108, 88112, 88172, 88173, 88177) so the service, specimen technique, and interpretation are clearly supported.

    • Ensure the record links the procedure performed to the appropriate code (e.g., concentration technique, liquid‑based preparation, FNA adequacy assessments)
    Denial Risk

    Denial risk for cytology-based breast cancer diagnosis, screening, or risk assessment

    Claims for cytologic analysis of epithelial cells (nipple aspiration, FNA, ductal lavage) to diagnose, screen for, or assess breast cancer risk do not meet criteria per this policy and may be denied.

    • Cytologic analysis for diagnosis/screening/risk assessment is considered not medically necessary and at risk for denial
    Billing Rule

    Procedure codes are reference only — verify appropriate coding

    Procedure codes in this policy are provided as a general reference and may not be all‑inclusive; billing an inappropriate or unsupported code could affect claim processing or lead to adjudication issues.

    • Policy note: procedure codes are for reference and may not cover all applicable codes
    • Verify that the code billed accurately describes the service performed
    Note

    Other provider responsibilities: verify benefits, include supporting documentation, and follow applicable regulations

    Ensure remaining provider-action responsibilities are completed: verify member benefit coverage and Medicare/Medicaid applicability, and include documentation that justifies any requested authorization in accordance with the member’s benefit and applicable state/federal regulations.

    • Confirm applicability of Medicare/Medicaid policy when conflicts exist
    • Include supporting documentation with authorization requests showing medical necessity and benefit coverage
    • Maintain records of cytopathology technique and interpretation consistent with billing
    Evidence contextNAF has been evaluated for diagnostic utility and biomarker profiling in breast cancer research (see cited studies).
    LBC — Liquid Based Cytology
    TermLBC (Liquid Based Cytology)
    DefinitionA laboratory cytology preparation method that uses liquid-based slide preparation and selective cellular enrichment to improve specimen quality and diagnostic yield compared with conventional smear methods.
    Performance noteStudy (Zhu et al. 2025) reported higher sensitivity and specificity for LBC versus conventional smear cytology in nipple discharge analysis (LBC sensitivity 40% vs CSC 22%; specificity LBC 100% vs CSC 95.2%).
    CSC — Conventional Smear Cytology
    TermCSC (Conventional Smear Cytology)
    DefinitionTraditional smear cytology technique in which cells are smeared directly onto slides for microscopic examination.
    Performance noteReported lower diagnostic sensitivity compared with LBC for nipple discharge specimens (Zhu et al. 2025).
    Cytopathology techniques and CPT code descriptions
    88108Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique).
    88112Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal.
    88172Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site.
    88173Cytopathology, evaluation of fine needle aspirate; interpretation and report.
    88177Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (list separately in addition to code for primary procedure).
    Studies have measured hormone concentrations in NAF (e.g., DHEA) and evaluated associations with breast cancer risk (Chatterton et al. 2016).
    Evidence statusMultiple references (including systematic reviews and observational studies) examine NAF biomarkers, but the policy concludes insufficient evidence to support clinical use for diagnosis, screening, or risk assessment.
    2026-03-05evidence_publication

    NCCN updated Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis (V1.2026).

    2026-06-16governance_approval

    Original documentation — policy governance approved.

    2026-10-01policy_effective_dateLatest

    Policy became effective on this date.